Prophylactic treatment for prevention of joint disease in hemophilia - Cost versus benefit

New England Journal of Medicine

Volumn 357, Issue 6, 2007, Pages 603-605

  Roosendaal, Goris ^a   Lafeber, Floris ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTHROPATHY; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; EDITORIAL; FOLLOW UP; HEALTH CARE COST; HEMARTHROSIS; HEMOPHILIA; HUMAN; NUCLEAR MAGNETIC RESONANCE; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROPHYLAXIS; COST BENEFIT ANALYSIS; ECONOMICS; HEMOPHILIA A; MALE; NOTE;

COST-BENEFIT ANALYSIS; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; JOINT DISEASES; MALE;

EID: 34547820908     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078098     Document Type: Editorial

References (14)

1. Roosendaal G, van Rinsum AC, Vianen ME, van den Berg HM, Lafeber FP, Bijlsma JW. Haemophilic arthropathy resembles degenerative rather than inflammatory joint disease. Histopathology 1999;34:144-53.
2. Wen FQ, Jabber AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc Proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. Blood 2002;100:912-6.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
4. Liesner RJ, Khair K, Hann IM. The impact of prophyactic treatment on children with severe haemophilia. Br J Haematol 1996;92:973-8.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994;236:391-9.
6. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
7. Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991;13:280-7.
8. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood 2002;99:2337-41.
9. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? The German experience. Haemophilia 1998;4:413-7.
10. Jansen NW, Roosendaal G, Bijlsma JW, Degroot J, Lafeber FP. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum 2007;56:199-207.
11. Hooiveld M, Roosendaal G, Vianen M, van den Berg M, Bijlsma J, Lafeber F. Blood-induced joint damage: longterm effects in vitro and in vivo. J Rheumatol 2003;30:339-44.
12. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005;90:494-8.
13. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006;12:Suppl 3:117-21.
14. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105:1109-13.